Skip to content
Search AI Powered

Latest Stories

New Treatment Stops Migraines Before They Start

New Treatment Stops Migraines Before They Start
Woman with head in hands

A new drug therapy could transform the lives of chronic migraine sufferers.

[DIGEST: King5 News, NBC, Mayo, P&T Community]

People who suffer from migraines may be able to prevent them months in advance, thanks to an experimental new treatment delivered intravenously four times a year. If that sounds extreme, consider this: Migraines, which can be accompanied by nausea and vomiting, extreme sensitivity to light and sound, visual disturbances, numbness in extremities, and debilitating pain, affect up to 38 million people in the U.S. and cost $36 billion in lost productivity and health care costs every year. In other words, migraines are no ordinary headache.


“The quality of life for people with migraine headaches is still very poor. They’re not able to function, they're not able to have a family life, personal life. It’s a very severe form of illness. People tend to underestimate its significance,” said Dr. Arif Khan, medical director of the Northwest Clinical Research Center, which is guiding 2,000 migraine sufferers through drug trials of a new treatment that could dramatically improve their quality of life.

The Washington-based Alder Biopharmaceutical has developed the drug, which is in Phase 2 of clinical trials. It is designed to eliminate or reduce the frequency of migraines for patients who chronically suffer from attacks. This preventative treatment is unique among migraine drugs; other treatments on the market are designed for use only after the symptoms begin.

“We’re taking a prevention strategy, we’re putting a long-acting, safe agent on board for the patient. A single dose of the drug will last over three months to prevent the initiation of that migraine from the get-go,” said Randy Schatzman, president of Alder Biopharmaceuticals.

The Alder drug, called eptinezumab, is administered intravenously in a 30-minute office visit every three months. It’s designed for people who suffer frequent migraines — some people have as many as 17 attacks a month, said Schatzman. Migraines can last several hours or even days and severely impact the lives of the people who suffer from them. The new drug, which will undergo more testing before it reaches the Food and Drug Administration for approval, is designed to improve quality of life for these extreme cases.

“I think that it should be fast-tracked by the FDA and hopefully we’ll have it on the market in the next two to three years,” said Khan.

Eptinezumab is a monoclonal antibody that inhibits the calcitonin gene-related peptide, a small protein involved in the transmission of pain experienced in migraine. Patients treated in the trial experienced results ranging from 27 to 100 percent relief from migraines over the three months following the treatment.

Migraines affect people of all ages and can be triggered by stress, hormones, changes in the weather, certain foods and beverages, sleep disorders, and certain medications. There may also be a genetic component to the disorder.

More from News

Donald Trump; Kamala Harris
Joe Raedle/Getty Images; Andrew Harnik/Getty Images

Trump Unveils His New Nickname For Kamala Harris In Unhinged Rant—And People Are Not Impressed

Former President Donald Trump seems to have landed on his latest nickname for Vice President Kamala Harris in a new typo-ridden Truth Social post. And it's not going over too well.

Trump's attack against Harris came after President Joe Biden dropped out of the 2024 race and endorsed Harris as his successor, completely upending the presidential contest.

Keep ReadingShow less
Joe and Jill Biden
Paul Morigi/Getty Images

Jill Biden's Simple Emoji Reaction To Joe Dropping Out Of The Race Sparks A Flurry Of Jokes

People couldn't believe how unbothered First Lady Dr. Jill Biden seemed to be after she posted an emoji of hearts in response to her husband President Joe Biden's announcement about dropping out of the presidential race, sparking a flurry of jokes.

Earlier, the president took to X, formerly Twitter, to share that "it is in the best interest of my party and the country for me to stand down and to focus solely on fulfilling my duties as President for the remainder of my term." He thanked Vice President Kamala Harris for being "an extraordinary partner" and later endorsed her to be his successor.

Keep ReadingShow less
Lady Gaga
David Jon/Getty Images for HBO

Lady Gaga Was Just Spotted In Paris—And Fans Think They Know Why

Lady Gaga recently fueled rumors regarding her potential performance at the 2024 Paris Olympics closing ceremony.

Speculation began on July 11 after French outlet Purepeople reported the news, and fans noticed that Thomas Jolly, the artistic director for the ceremonies, had followed Gaga on Instagram.

Keep ReadingShow less
Instagram screenshots of Tom Daley and cardboard bed
@tomdaley/Instagram

Diver Tom Daley Hilariously Tests Out 'Anti-Sex' Cardboard Beds For Paris Olympics Athletes

A couple of months ago, the internet was buzzing with news that "anti-sex" beds were installed at the Olympic village ahead of the 2024 summer games in Paris in an effort to keep competitors from... well, you know.

Thankfully for all of social media and, of course, the other athletes, British diver Tom Daley has arrived in Paris and conducted some field research on the beds, which are made from completely recyclable mattresses and cardboard frames.

Keep ReadingShow less
Chadwick Boseman; Kamala Harris
Sarah Morris/FilmMagic/Getty Images; Anna Moneymaker/Getty Images

Chadwick Boseman's Final Tweet Supporting Harris Resurfaces—And Fans Are Feeling Emotional

On Sunday, President Biden announced he would not be seeking a second term as president and pulled out of the presidential race.

Soon after, he endorsed Vice President Kamala Harris.

Keep ReadingShow less